Some Cancer Drugs May Boost Arthritis Risk

A class of cancer immunotherapy drugs may increase the risk of developing joint and tissue diseases, such as arthritis.

Researchers at the Johns Hopkins University School of Medicinein Baltimore  have discussed 13 case reports of patients who were taking Yervoy (ipilimumab) and/or Opdivo (nivolumab) between 2012 and this year and developed new-onset arthritis or sicca syndrome, a set of autoimmune conditions causing dry eyes and mouth, including Sjogren’s syndrome.

Yervoy and Opdivo are in a class of cancer drugs known as checkpoint inhibitors. For patients with melanoma, a type of skin cancer, the drugs are taken together. A third checkpoint inhibitor on the market is Keytruda (pembrolizumab). Opdivo and Keytruda can also be used to treat a type of lung cancer.

“In 2015, our rheumatology clinic started getting more and more referrals from our oncology department to evaluate patients treated with immunotherapies,” lead study author Laura C. Cappelli, MD, a rheumatologist at Johns Hopkins, said in a statement. “And the patients we saw had very severe, highly inflammatory arthritis. They needed even higher doses of steroids to control their symptoms compared to what is needed in other forms of inflammatory arthritis, like rheumatoid arthritis.”

However, the researchers noted that the 13 patients on checkpoint inhibitors represented only 1.5% of the patients between 2012 and 2016 who were taking one or both of the drugs at the Kimmel Cancer Center. Also, additional research is needed to determine a cause-and-effect relationship.

Cappelli said she wants the case reports, which were published in the Annals of the Rheumatic Diseases, to raise awareness among both patients and doctors of the side effects that may occur with these drugs.

“It is important when weighing the risk-benefit ratio of prescribing these drugs,” she said. “And it’s important for people to be on the lookout for symptoms so they can see a rheumatologist early in an effort to prevent or limit joint damage.”


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement